新型コロナウイルス感染症（COVID-19）に関連した検査室 …
1 主要要求事項（core requirements）：WHO「実験室バイオセーフティ指針（Laboratory biosafety manual）第4版」で 定める最低限の要求事項であり、検査室バイオセーフティの基礎でありながらその不可欠な一部でもあるリスク管理措 置の組み合わせを示すものである。
Download 新型コロナウイルス感染症（COVID-19）に関連した検査室 …
Information
Domain:
Source:
Link to this page:
Documents from same domain
GOOD DOCUMENTATION AND QUALITY …
extranet.who.intGOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme
6. Process control— introduction to quality control
extranet.who.intLaboratory Quality Management System 73 6-1: Introduction QC for varying methods To avoid confusion, the term "quality control" will be used here to mean use
Vaccine Handling BCG - World Health Organization
extranet.who.intEnsuring the quality of vaccines at country level: Guidelines for health staff At the higher levels of the cold chain, i.e. at the national (central) and
Guidelines: Saturated fatty acid and trans-fatty acid ...
extranet.who.intthe WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health – participated in the WHO guideline development meetings.
SUMMARY OF PRODUCT CHARACTERISTICS
extranet.who.intThis product is intended for use in children. Nonetheless, safety information is provided with respect to adult health issues such as liver disease, pregnancy and lactation, to allow full access to all
SUMMARY OF PRODUCT CHARACTERISTICS
extranet.who.intArtesunate 60 mg for injection WHOPAR part 4 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 . SUMMARY OF PRODUCT CHARACTERISTICS
Varicella Contraindications - WHO/OMS: Extranet …
extranet.who.intContraindications Varicella vaccines (WHO position paper) In immunocompromised persons, including patients with advanced HIV infection, varicella vaccination is currently contraindicated for fear of
Anexo 1 Buenas prácticas de la OMS para …
extranet.who.int2 Consideraciones generales El Comité de Expertos sobre Especificaciones para Productos Farmacéuticos de la OMS adoptó en 1999 las guías tituladas Buenas prácticas para laboratorios nacionales de control farmacéutico de la OMS, que fueron publicadas como Anexo 3 de la Serie de Informes Técnicos de la OMS, No. 902, 2002.
Pneumococcal Contraindications - WHO/OMS: …
extranet.who.intContraindications Pneumococcal vaccines (WHO position paper) There are no absolute contraindications to vaccination with pneumococcal polysaccharide vaccine except for an anaphylactic reaction to the previous
Contraindications BCG - WHO/OMS: Extranet Systems
extranet.who.intRubella vaccines (WHO position paper) Rubella vaccination should be avoided in pregnancy because of the theoretical, but never demonstrated, teratogenic risk.
Related documents
Regulatory Basics for Facility Design (WHO GMP): Biosafety ...
www.dcvmn.orgBiosafety Level Laboratory Type Laboratory Practices Safety Equipment 1 Basic –BSL 1 Basic teaching, research Good microbiological techniques (GMT) Open work bench 2 Basic –BSL 2 Primary health and diagnostic services, research GMT + protective clothing, biohazard sign Level 01 + BSC for potential aerosols 3 Containment – BSL 3 Special ...
4 Biosafety Levels - Centers for Disease Control and ...
www.cdc.gov4 Biosafety Lab Levels •BSL1 1.Controlled access 2.Hand washing sink 3.Sharp hazards warning policy 4.Personal protective equipment 5.Laboratory bench 6.Autoclave •BSL2 1.Controlled access 2.Hand washing sink 3.Sharp hazards warning policy 4.Physical containment device 5.Personal protective equipment 6.Laboratory bench 7.Autoclave
THE CALIFORNIA ORKPLACE UIDE TO AEROSOL
www.dir.ca.govwhich Biosafety in Microbiological and Biomedical Laboratories (BMBL) recommends biosafety level 3 (BSL 3) or above, pathogens for which the biosafety officer recommends BSL 3 or above, and novel or unknown pathogens . Note: Some diseases or pathogens, such as SARS and SARS coronavirus, appear on more than one list.
Laboratory Biosafety and Biosecurity Risk Assessment ...
www.cdc.govA biosafety risk assessment allows a laboratory to determine the relative level of risks its different activities pose and helps guide risk mitigation decisions so they are targeted to the most important risk. A biosafety risk assessment should consider every activity and procedure in a laboratory that involves infectious disease agents.
Governments advance negotiations on ambitious global ...
www.cbd.intMar 29, 2022 · Biosafety and the Nagoya Protocol on Access and Benefit-Sharing are supplementary agreements to the CBD. The Cartagena Protocol, which entered into force 11 September 2003, seeks to protect biodiversity from the potential risks posed by living modified organisms resulting from modern biotechnology. To